-
公开(公告)号:EP2844642B1
公开(公告)日:2019-11-13
申请号:EP13788352.6
申请日:2013-03-15
申请人: ARIAD PHARMACEUTICALS, INC. , Zhu, Xiaotian , Wang, Yihan , Shakespeare, William C. , Huang, Wei-Sheng , Dalgarno, David C.
发明人: ZHU, Xiaotian , WANG, Yihan , SHAKESPEARE, William, C. , HUANG, Wei-Sheng , DALGARNO, David, C.
IPC分类号: C07D239/48 , C07D403/12 , C07F9/6561 , C07F9/6584 , C07F9/6512 , C07F9/6521 , A61K31/505 , A61K31/506 , A61P35/00
-
2.
公开(公告)号:EP2844642A1
公开(公告)日:2015-03-11
申请号:EP13788352.6
申请日:2013-03-15
申请人: ARIAD PHARMACEUTICALS, INC. , Zhu, Xiaotian , Wang, Yihan , Shakespeare, William C. , Huang, Wei-Sheng , Dalgarno, David C.
发明人: ZHU, Xiaotian , WANG, Yihan , SHAKESPEARE, William, C. , HUANG, Wei-Sheng , DALGARNO, David, C.
IPC分类号: C07D239/48
摘要: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.
-
公开(公告)号:EP2841062A1
公开(公告)日:2015-03-04
申请号:EP13782134.4
申请日:2013-03-12
申请人: ARIAD PHARMACEUTICALS, INC. , Gozgit, Joseph M. , Rivera, Victor M. , Shakespeare, William C. , Zhu, Xiaotian , Dalgarno, David C.
发明人: GOZGIT, Joseph, M. , RIVERA, Victor, M. , SHAKESPEARE, William, C. , ZHU, Xiaotian , DALGARNO, David, C.
IPC分类号: A61K31/165
CPC分类号: C07D487/04 , A61K31/437 , A61K31/496 , A61K31/4985 , A61K31/5025 , A61K31/5377 , C07D471/04 , C07D473/34
摘要: The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.
摘要翻译: 本发明公开了通过施用式1的化合物或其药学上可接受的盐,溶剂化物或水合物来治疗或预防RAF激酶介导的疾病或病症的方法和组合物,其中变量如本文所定义。
-
公开(公告)号:EP3778584A1
公开(公告)日:2021-02-17
申请号:EP20178478.2
申请日:2015-05-13
发明人: HUANG, Wei-sheng , GONG, Yongjin , LI, Feng , BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , KOHLMANN, Anna , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , ZHU, Xiaotian , WEST, Angela, V. , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun
IPC分类号: C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D471/04
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
-
公开(公告)号:EP3210609A1
公开(公告)日:2017-08-30
申请号:EP17162419.0
申请日:2009-05-21
发明人: WANG, Yihan , HUANG, Wei-Sheng , LIU, Shuangying , SHAKESPEARE, William, C. , THOMAS, R., Mathew , QI, Jiwei , LI, Feng , ZHU, Xiaotian , KOHLMANN, Anna , DALGARNO, David, C. , ROMERO, Jan, Antoinette, C. , ZOU, Dong
IPC分类号: A61K31/505 , A61K31/513
CPC分类号: C07F9/6533 , C07D239/48 , C07F9/587 , C07F9/650941 , C07F9/65122 , C07F9/65127 , C07F9/65216 , C07F9/65217 , C07F9/65218 , C07F9/65583 , C07F9/65586 , C07F9/6561 , C07F9/65616 , C07F9/65685 , C07F9/657172 , C07F9/65846
摘要: The invention features compounds of the general formula (VIa) in which the variable groups are as defined herein, and to their preparation and use.
-
公开(公告)号:EP3157916A1
公开(公告)日:2017-04-26
申请号:EP15810340.8
申请日:2015-05-13
发明人: HUANG, Wei-sheng , GONG, Yongjin , LI, Feng , BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , KOHLMANN, Anna , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , ZHU, Xiaotian , WEST, Angela, V. , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun
IPC分类号: C07D403/14 , C07D473/16
CPC分类号: C07D471/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14 , C07F9/65583
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
摘要翻译: 本文描述了调节激酶活性的化合物和药物组合物,包括突变型EGFR和突变型HER2激酶活性,以及化合物,药物组合物和治疗与激酶活性相关的疾病和病症的方法,包括突变型EGFR和突变型HER2活性。
-
7.
公开(公告)号:EP2704572B1
公开(公告)日:2015-12-30
申请号:EP12779411.3
申请日:2012-05-04
发明人: DALGARNO, David, C. , HUANG, Wei-sheng , SHAKESPEARE, William, C. , WANG, Yihan , ZHU, Xiaotian
IPC分类号: A01N43/54 , A01N43/66 , A61K31/505 , A61K31/53 , C07D401/00
CPC分类号: C07D239/48 , A61K31/4025 , A61K31/444 , A61K31/4523 , A61K31/505 , A61K31/506 , A61K31/538 , A61K31/553 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
摘要: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: wherein the variables are as defined herein.
-
公开(公告)号:EP1408978A2
公开(公告)日:2004-04-21
申请号:EP02742236.9
申请日:2002-06-21
发明人: METCALF, Chester, A., III , SHAKESPEARE, William, C. , SAWYER, Tomi, K. , WANG, Yihan , BOHACEK, Regine
IPC分类号: A61K31/505 , C07D409/14
CPC分类号: C07D239/42 , C07D401/04 , C07D403/04 , C07F9/65122 , C07F9/65127 , C07F9/65583
摘要: This invention relates to compounds of the general formula (I), in which R?A, RB, RC, RD¿, and z are as defined herein, and to their preparation and use.
-
公开(公告)号:EP3409669B1
公开(公告)日:2020-10-07
申请号:EP18182201.6
申请日:2015-05-13
发明人: HUANG, Wei-sheng , GONG, Yongjin , LI, Feng , BENCIVENGA, Nicholas, E. , DALGARNO, David, C. , KOHLMANN, Anna , SHAKESPEARE, William, C. , THOMAS, Ranny, M. , ZHU, Xiaotian , WEST, Angela, V. , YOUNGSAYE, Willmen , ZHANG, Yun , ZHOU, Tianjun
IPC分类号: C07D403/04 , C07D401/14 , C07D405/14 , C07D403/14 , C07D405/12 , C07D471/04 , C07D401/04
-
公开(公告)号:EP2024366B1
公开(公告)日:2015-09-16
申请号:EP07756233.8
申请日:2007-05-08
发明人: SHAKESPEARE, William, C. , HUANG, Wei-sheng , DALGARNO, David, C. , ZHU, Xiaotian , THOMAS, R., Mathew , WANG, Yihan , QI, Jiwei , SUNDARAMOORTHI, Rajeswari , ZOU, Dong , METCALF, Chester, A. , SAWYER, Tomi, K. , ROMERO, Jan Antoinette, C.
IPC分类号: C07D231/12 , C07D233/64 , C07D233/90 , C07D403/14 , C07D417/12 , C07D417/14
CPC分类号: C07D231/12 , C07D233/64 , C07D233/90 , C07D277/40 , C07D403/12 , C07D403/14 , C07D417/12 , C07D417/14
摘要: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
-
-
-
-
-
-
-
-
-